Curis, Inc. (NASDAQ:CRIS) Posts Earnings Results, Misses Estimates By $0.01 EPS
Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.01, Bloomberg Earnings reports. The company had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.09) earnings per share.
Curis (NASDAQ CRIS) traded up 15.44% during mid-day trading on Friday, reaching $1.72. 653,870 shares of the company were exchanged. The stock’s 50-day moving average price is $1.98 and its 200-day moving average price is $2.32. Curis has a 1-year low of $1.49 and a 1-year high of $3.72. The stock’s market capitalization is $247.29 million.
Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its stake in shares of Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Curis during the first quarter worth about $105,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Curis by 22.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after buying an additional 7,638 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Curis during the second quarter worth about $163,000. Finally, BB&T Securities LLC acquired a new stake in shares of Curis during the second quarter worth about $179,000. 51.68% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have recently commented on CRIS. Zacks Investment Research cut shares of Curis from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Cowen and Company restated a “buy” rating on shares of Curis in a report on Friday, May 5th. BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Curis presently has a consensus rating of “Hold” and a consensus target price of $5.88.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.